A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Conditions
- Breast Neoplasms
- Gastroesophageal Junction Adenocarcinoma
- HER2 Low Breast Neoplasms
- HER2 Positive Breast Neoplasms
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Metastatic Breast Cancer
- Metastatic Gastric Cancer
- Advanced Breast Cancer
- Advanced Gastric Cancer
Interventions
- DRUG: disitamab vedotin
- DRUG: tucatinib
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Collaborators